Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force

(E-pub Ahead of Print)

Author(s): Mahfoozur Rahman, Sarwar Beg, Vikas Kumar, Sohail Akhter*.

Journal Name: Current Nanomedicine
Formerly Recent Patents on Nanomedicine

Become EABM
Become Reviewer

Abstract:

Alec Bangham, first described liposomes as spherical vesicles which characterized by bilayer of lipid with central aqueous cavity. Liposomes are the first nanovesicular drug delivery carriers, which successfully translated into real time clinical application and gained great potential in the past 30 years. The characteristics of liposomes are to encapsulate both hydrophilic and hydrophobic drugs, their biocompatibility and biodegradability makes it attractive nanocarriers in drug delivery area. Apart from this, great technical advances has been made such as remote drug loading techniques, second generation liposomes like stealth liposomes, cationic liposomes, triggered release liposomes and ligand targeted liposomes having combinations of drugs. This led to widespread use of liposomes in various areas including cancer as anticancer therapeutics, diagnostics and imaging agents. This review presents the extensive discussion of various liposomes and its applications in cancer treatment.

Keywords: Phospholipids, Liposomes, ligand targeted liposomes, Cancer, Anticancer drug, and Doxil Inflammatory disorders, Psoriasis, Cationic liposomes, Rheumatoid Arthritis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2468187309666190618171332

Special-new-year-discount